Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
Rhea-AI Summary
Cardiol Therapeutics (NASDAQ:CRDL) will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ in New York.
The session is scheduled for May 19, 2026 at 1:30 p.m. EDT, with a live webcast and a replay available for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – CRDL
In the May 14 session, CRDL gained 0.74%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Phase II results | Positive | -1.5% | Phase II MAvERIC results accepted in a major cardiology journal. |
| Apr 28 | Trial expansion | Positive | -2.1% | U.S. MAVERIC Phase III network expanded with additional clinical centers. |
| Apr 14 | Investor interview | Positive | +2.9% | Live interview highlighting MAVERIC Phase III and ARCHER Phase II data. |
| Apr 01 | Operations update | Positive | +3.7% | Year-end 2025 update on trials, IP, financing, and pipeline progress. |
| Feb 25 | Conference appearance | Neutral | +2.5% | Announcement of TD Cowen healthcare conference presentation and webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinically positive updates sometimes saw negative 24h reactions, while broader operations and conference news more often aligned with positive price moves.
Over the past six months, CRDL has combined clinical progress with active investor outreach. Positive Phase II data for CardiolRx and expansion of the Phase III MAVERIC trial to up to 25 sites were followed by 24h declines of -1.52% and -2.14%, respectively. In contrast, the year-end 2025 operations update on Apr 01 and a clinical/investor interview on Apr 14 coincided with gains of 3.7% and 2.94%. A prior conference appearance on Feb 25 also aligned with a 2.49% move.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the Fireside Chat will be accessible under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/). The replay will be available for 90 days following the conference.
About Cardiol Therapeutics
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The
The ARCHER Program also studied CardiolRx™, specifically in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.
The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in
For more information about Cardiol Therapeutics, please visit cardiolrx.com.
Cautionary statement regarding forward-looking information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and
View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiol-therapeutics-to-participate-in-fireside-chat-at-hc-wainwright-4th-annual-bioconnect-investor-conference-at-the-nasdaq-302772040.html
SOURCE Cardiol Therapeutics Inc.